Kailera Therapeutics KLRA
NASDAQ KLRA
$13.27 +0.06 (+0.45%)
At close: Nov 13, 2026 · 4:00 PM EST

Kailera Therapeutics (KLRA) Return on Sales [ROS] (2025 - 2026)

Updated

Kailera Therapeutics (KLRA) reported Return on Sales [ROS] of -1481.11% for Q1 2026, down 259.73 percentage points from -1221.37% a year earlier.

Analysis

Kailera Therapeutics (KLRA) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

Over the twelve months ended Mar 31, 2026, Kailera Therapeutics' Return on Sales [ROS] came in at -7383.64%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 24.35%
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 36.01%
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 30.74%
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 29.12%
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 35.79%
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 41.71%
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 32.98%
10 Kailera Therapeutics 1.72 Bn -1.16 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -1,481.11%
Mar 31, 2025 -1,221.37%
API Access

Kailera Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=KLRA&period=max&api_key=YOUR_API_KEY